The financials
Twist Bioscience Corporation by the numbers
Twist Bioscience Corporation (TWST) reported revenue of $118M in Q3 2026 (quarter ended June 30, 2026), up 23% from the same quarter a year earlier. That came with a gross margin of 53% and net loss of $35M. For the full year FY2025, revenue was $377M (+20% year on year) and net income −$78M. Its largest product in 2026-Q1 was Ngs Tools at $57M, 52% of the disclosed total, just ahead of Antibody Discovery at 48%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $118M | $96M | +23% |
| Gross profit | $62M | $51M | +22% |
| Operating income | −$36M | −$30M | n/a |
| Net income | −$35M | $20M | to a loss |
| Diluted EPS | −$0.56 | $0.33 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Ngs Tools | $57M | 52% |
| Antibody Discovery | $53M | 48% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $110.7M (+6.8%)
Antibody Discovery grew +28% year on yearNgs Tools +12% year on year
Segment Latestquarter on quarteryear on year
- Ngs Tools$57.4M$57.4MQoQ +9.1%year on year +12%+9.1%+12%
- Antibody Discovery$53.3M$53.3MQoQ +4.3%year on year +28%+4.3%+28%
- Dna And Biopharma Libraries--QoQ -year on year ---
- Oligo Pools--QoQ -year on year ---
- Synthetic Genes--QoQ -year on year ---
Diagnostics & Research
Ranks #4 of 29 by Smart Score